Erbitux (cetuximab)

pCPA File Number: 23625

Negotiation Status:

Under consideration for negotiation

Indication(s):

Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CDA-AMC Project Number:

PC0428-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable